|
|
Post by Clement on Nov 5, 2024 9:50:22 GMT -5
Suppose there's a big pharma who knows the API and the patients very well. This BP likes to run their own trials and knows exactly how these further trials should be planned and managed. They could plan the transition to commercialization as precisely as possible. Now would be the time for them to get serious about an offer.
|
|
|
|
Post by agedhippie on Nov 5, 2024 10:12:27 GMT -5
Dont think there is a real reason to hurry due to patent expiration in 2026. Especially if this is a II/III trial. Should shoot for late 2026 FDA approval. www.greyb.com/blog/ofev-patent-expiration/Composition of Matter US6762180B1 Expires on Apr 01, 2026 Speed matters. The last thing you want is a patent getting filed before you file for approval. As long as MNKD file for approval before any unexpected patent turns up in the Orange Book and extends the expiration date there is no issue. This is what LQDA did to UTHR over the ILD indication - LQDA filed before the UTHR patent was in the Orange Book. |
|
|
|
Post by peppy on Nov 5, 2024 10:23:35 GMT -5
Dont think there is a real reason to hurry due to patent expiration in 2026. Especially if this is a II/III trial. Should shoot for late 2026 FDA approval. www.greyb.com/blog/ofev-patent-expiration/Composition of Matter US6762180B1 Expires on Apr 01, 2026 Speed matters. The last thing you want is a patent getting filed before you file for approval. As long as MNKD file for approval before any unexpected patent turns up in the Orange Book and extends the expiration date there is no issue. This is what LQDA did to UTHR over the ILD indication - LQDA filed before the UTHR patent was in the Orange Book. Thanks Aged, agedhippie , as long as you are here lurking, what can you tell me about the convertible bonds? If the call is $6.77, how high and MNKD share price go as we are waiting for the agreement timeframes to pass? Or questions that make sense to you....what can you tell me about the conversion process? |
|
